StockNews.com began coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) in a research report released on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock. AGLE has been the topic of a number of other research reports. Wells Fargo & Company downgraded Aeglea BioTherapeutics from an overweight rating to […]
Research Analysts’ new coverage for Wednesday, June 14th: BNP Paribas began coverage on shares of Agree Realty (NYSE:ADC). The firm issued an outperform rating and a $80.00 target price on the stock. StockNews.com initiated coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE). The firm issued a hold rating on the stock. StockNews.com assumed coverage on shares […]
Shares of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE – Get Rating) have earned a consensus rating of “Hold” from the six analysts that are currently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating. The average 1-year target price among analysts that have updated their coverage on the stock in […]
StockNews.com started coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) in a report released on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock. Other analysts have also recently issued reports about the stock. Jonestrading reiterated a hold rating on shares of Aeglea BioTherapeutics in a research note on Wednesday, […]